J Korean Med Assoc Search


J Korean Med Assoc > Volume 54(11); 2011 > Article
Journal of the Korean Medical Association 2011;54(11):1191-1198.
DOI: https://doi.org/10.5124/jkma.2011.54.11.1191   
Oral chemotherapeutic agents in current use
Namsu Lee, Kyoung Ha Kim, Sang Cheol Lee
Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea. mdnslee@schmc.ac.kr
Currently, 10% of cancer chemotherapy is provided to patients by oral formulation; however, by 2013 this percentage is predicted to increase to 25%. Chemotherapy is traditionally given by injection. Oral chemotherapy has been developed as a more convenient method for treating patients. Oral chemotherapy offers many advantages including the elimination of pain often caused by injections, the lack of fees for administering intravenous drugs, more time at home for patients, and a patient's increased sense of autonomy. The role of oral chemotherapy has been expanding because of the potential advantages in convenience and better quality of life for patients, and in the cost-effectiveness of treatment as compared to intravenous chemotherapy. A number of novel oral targeted and cytotoxic chemotherapeutic agents are entering the market or are in development. Many of the agents display significant clinical activity against various cancers. The growing availability of effective oral chemotherapy treatments, especially the new class of 'targeted biologic therapies', is one of the wonderful recent advances in cancer care. This manuscript describes the progress of clinical development and efficacy of these newly developed chemotherapeutic agents.
Key Words: Neoplasms, Drug therapy, Oral administration


Browse all articles >

Editorial Office
Samgu B/D 7F, 40 Cheongpa-ro, Youngsan-gu, Seoul 04373, Korea
Tel: +82-1566-2844    Fax: +82-2-792-5208    E-mail: jkmamaster@gmail.com                

Copyright © 2022 by Korean Medical Association.

Developed in M2PI

Close layer
prev next